Myasthaenia gravis in pregnancy, delivery and newborn.
Adrenal Cortex Hormones
/ adverse effects
Arthrogryposis
/ etiology
Breast Feeding
Cholinesterase Inhibitors
/ therapeutic use
Cleft Palate
/ chemically induced
Congenital Abnormalities
/ etiology
Delivery, Obstetric
Disease Progression
Female
Fetal Membranes, Premature Rupture
/ etiology
Humans
Infant, Newborn
Myasthenia Gravis
/ complications
Patient Care Team
Perinatal Mortality
Polyhydramnios
/ etiology
Pregnancy
Pregnancy Complications
/ drug therapy
Pregnancy Trimester, First
Pyridostigmine Bromide
/ therapeutic use
Recurrence
Journal
Minerva ginecologica
ISSN: 1827-1650
Titre abrégé: Minerva Ginecol
Pays: Italy
ID NLM: 0400731
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Myasthaenia gravis (MG) is the most common disease of the neuromuscular junction; clinical presentation of the disease includes a variety of symptoms, the most frequent beign the only ocular muscles involvement, to the generalized myasthenic crisis with diaphragmatic impairment and respiratory insufficiency. It is most common in women between 20 ad 40 years. We performed a comprehensive search of relevant studies from January1990 to Dicember 2019 to ensure all possible studies were captured. A systematic search of Pubmed databases was conducted. Pregnancy has an unpredictable and variable effect on the clinical course of MG; however, a stable disease before is likely not to relapse during pregnancy. exacerbations can still occur more often during the first trimester and the post partum period. The transplacental passage of antibodies results in a neonatal transient disease, whereas the major concern is related to foetal malformations such as fetal arthrogryposis and polyhydramnios. The overall neonatal outcome described in literature is variable, perinatal mortality in women with MG is generally the same as non affected patients, although in one study the risk of premature rupture of the membranes was higher. Treatment of MG in pregnangncy includes pyridostigmine and corticosteroids, although the latter have been associated with higher risk of cleft palate, premature rupture of the membranes and preterm delivery. These drugs appear also to be safe in breastfeeding. In MG patients spontaneous vaginal delivery should be encouraged, for surgery could cause acute worsening of myasthenic symptoms; also an accurate anesthesiological evaluation must be performed prior to both general and local anesthesia due to increased risk of complications. Most of the myasthenic women could have uneventful pregnancy with good obstetrical outcomes, both for mother and neonate. However, a careful planning of pregnancy and multidisciplinary team approach, composed by neurologists, obstetricians, neonatologists and anesthesiologists, is required to manage these pregnancies.
Identifiants
pubmed: 32153161
pii: S0026-4784.20.04505-0
doi: 10.23736/S0026-4784.20.04505-0
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Cholinesterase Inhibitors
0
Pyridostigmine Bromide
KVI301NA53
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM